Researchers investigated outcomes following implementation of remote care that targeted effective control of hypertension, or elevated blood pressure (BP), and cholesterol management.
Diverse patient populations stand to benefit from a standardized remote blood pressure (BP) and cholesterol management program that targets reductions in hypertension and low-density lipoprotein cholesterol (LDL-C, or “bad” cholesterol), according to study findings published in JAMA Cardiology.
With dual main outcomes of changes to BP and LDL-C, the investigators of this study enrolled 10,803 patients from the Mass General Brigham (MGB) health system into a comprehensive remote program that monitored hypertension and cholesterol; the programs to monitor each are part of an ongoing initiative in the MGB health system, the authors noted. A majority of the patients (n = 8103) had high cholesterol only, 3658 had hypertension only, and 958 had high cholesterol and hypertension. All patients enrolled received education, home BP device integration, and medication titration—with 1266 patients requesting education only.
Their mean (SD) age was 65 (11.4) years, and most were female patients (56%) and White (72%). Also, 12% of patients identified as Black; 11%, Hispanic; and 16%, another race or multiple races (American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander, unknown, other, and declined to respond; consolidated owing to small numbers, the authors noted).
“Recent data suggest that rates of BP and lipid control have stagnated and even deteriorated,” the authors wrote. “The rate of risk factor control is even lower among certain racial and ethnic populations, those who live in rural geographic areas, and those with limited English proficiency.”
For the study period, BP readings topped 400,000 and there were 139,263 lab reports. Comparing findings seen in office and at home before program enrollment, the mean (SD) BPs were 150/83 (18/10) mm Hg and 145/83 (20/12) mm Hg, respectively.
After program enrollment and among those who chose remote medication management, mean (SD) BP measures at the 6- and 12-month marks, respectively, showed decreases of 8.7/3.8 (21.4/12.4) mm Hg and 9.7/5.2 (22.2/12.6) mm Hg. The decreases were markedly different compared with the patients who chose just to receive education: In this group, BP had dropped a mean (SD) of 1.5/0.7 (23.0/11.1) mm Hg at 6 months, but the 12-month data show a slight increase of 0.2/–1.9 (30.3/11.2) mm Hg (P < .001).
When considering cholesterol management, again, patients enrolled in remote medication management saw superior results. At 6 months, their LDL-C had dropped a mean (SD) of 35.4 (43.1) mg/dL and at 12 months, 37.5 (43.9) mg/dL. In stark contrast, the patients who chose only education had respective LDL-C decreases of 9.3 (34.3) and 10.2 (35.5) mg/dL (P < .001). The mean (SD) overall LDL-C reduction was 46.2 (53.6) mg/dL (P < .001), but it was highest among the patients who had any historical LDL-C measure above 190 mg/dL, at 93.0 (50.4) mg/dL.
The authors’ analysis also showed the following results:
Approximately 10% of patients became unreachable over the course of the study, and follow-up with close to 30% of them found they dropped out because the program was not convenient, they were not comfortable taking more meds, they preferred direct interaction with their physicians, and they felt their condition was under control. Because of these reasons, the authors stress the importance of better education, health care professional coordination, and patient engagement.
“Further research on engagement strategies, incentives, and behavioral economics is required to understand reasons for noncompletion and interventions that may be able to promote goal attainment,” the authors concluded.
Reference
Blood AJ, Cannon CP, Gordon WJ, et al. Results of a remotely delivered hypertension and lipid program in more than 10 000 patients across a diverse health care network. JAMA Cardiol. Published online November 9, 2022. doi:10.1001/jamacardio.2022.4018
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More